Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases 6,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young purchased 6,000 shares of the stock in a transaction on Wednesday, February 5th. The shares were purchased at an average price of $5.65 per share, with a total value of $33,900.00. Following the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at approximately $169,500. The trade was a 25.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James Emmett Young also recently made the following trade(s):

• On Monday, January 27th, James Emmett Young acquired 24,000 shares of TriSalus Life Sciences stock. The shares were purchased at an average price of $5.40 per share, with a total value of $129,600.00.

TriSalus Life Sciences Stock Up 3.5 %

NASDAQ TLSI opened at $5.57 on Friday. TriSalus Life Sciences, Inc. has a 52 week low of $3.50 and a 52 week high of $10.42. The business has a 50 day moving average price of $4.68 and a 200-day moving average price of $4.75. The company has a market cap of $169.83 million, a price-to-earnings ratio of -2.24 and a beta of 0.51.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences during the third quarter worth about $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $108,000. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences in the third quarter worth approximately $184,000. Finally, Geode Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TLSI. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Canaccord Genuity Group dropped their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Northland Securities started coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, TriSalus Life Sciences currently has an average rating of “Buy” and an average target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.